Recommendations for the Use of Testosterone in Male Transgender^[*]

Abstract

Gender incongruence is defined as a condition in which an individual self-identifies and desires to have physical characteristics and social roles that connote the opposite biological sex. Gender dysphoria is when an individual displays the anxiety and/or depression disorders that result from the incongruity between the gender identity and the biological sex. The gender affirmation process must be performed by a multidisciplinary team. The main goal of the hormone treatment is to start the development of male physical characteristics by means of testosterone administration that may be offered to transgender men who are 18 years old or over. The use of testosterone is usually well tolerated and improves the quality of life. However, there is still lack of evidence regarding the effects and risks of the long-term use of this hormone. Many different pharmacological formulations have been used in the transsexualization process. The most commonly used formulation is the intramuscular testosterone esters in a short-term release injection, followed by testosterone cypionate or testosterone enanthate. In the majority of testosterone therapy protocols, the male physical characteristics can be seen in almost all users after 6 months of therapy, and the maximum virilization effects are usually achieved after 3 to 5 years of regular use of the hormone. To minimize risks, plasmatic testosterone levels should be kept within male physiological ranges (300 to 1,000 ng/dl) during hormonal treatment. It is recommended that transgender men under androgen therapy be monitored every 3 months during the 1st year of treatment and then, every 6 to 12 months.

Resumo

Incongruência de gênero é uma condição na qual o indivíduo se identifica, deseja viver e ser aceito como uma pessoa do gênero oposto ao designado por ocasião do nascimento. Na disforia de gênero o indivíduo manifesta ansiedade e sofrimento pelo desejo de viver e ser aceito como uma pessoa do gênero oposto ao designado ao nascimento. O processo transsexualizador requer trabalho em equipe multiprofissional. O objetivo do tratamento hormonal é induzir o aparecimento de características sexuais masculinas secundárias por meio da administração da testosterona em indivíduos com idade igual ou superior a 18 anos. O tratamento de estimulação androgênica costuma ser bem tolerado. Entretanto, ainda não existem evidências sobre os efeitos e riscos do uso da testosterona a longo prazo. Diferentes preparações farmacológicas da testosterona têm sido utilizadas. As mais utilizadas têm sido as injeções intramusculares de administração a curto prazo de ésteres, seguidas do cipionato de testosterona e do enantato de testosterona. Na maioria dos protocolos de tratamento observa-se o aparecimento de características corporais masculinas nos primeiros 6 meses, e a obtenção do máximo efeito da estimulação androgênica, após 3 a 5 anos de uso regular da testosterona. Recomenda-se a manutenção dos níveis plasmáticos de testosterona dentro dos limites fisiológicos para o sexo masculino (300 a 1.000 ng/dl), a fim de minimizar os riscos. A monitorização dos homens transgênero é recomendada a cada 3 meses durante o primeiro ano de tratamento e a seguir, a cada 6 a 12 meses.

Keywords

transgender men - gender incongruence - gender dysphoria

Palavras-chave

homens transgênero - incongruência de gênero - disforia de gênero

^* This revision was elaborated by the Specialized National Committees on Endocrine Gynecology at Federação Brasileira das Associações de Ginecologia e Obstetrícia. All authors are members of the Commission.

• References

• 1 Trum HW, Hoebeke P, Gooren LJ. Sex reassignment of transsexual people from a gynecologist's and urologist's perspective. Acta Obstet Gynecol Scand 2015; 94 (06) 563-567 . Doi: 10.1111/aogs.12618
• 2 Meriggiola MC, Berra M. Safety of hormonal treatment in transgenders. Curr Opin Endocrinol Diabetes Obes 2013; 20 (06) 565-569 . Doi: 10.1097/01.med.0000436187.95351.a9
• 3 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5^th ed. Washington, DC: American Psychiatric Association; 2013
• 4 Ministério da Saúde. Portaria No. 2.803, de 19 de novembro de 2013. http://bvsms.saude.gov.br/bvs/saudelegis/gm/2013/prt2803_19_11_2013.html . Accessed August 14, 2017
• 5 The World Professional Association for Transgender Health. Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, 7^th version. 2012. https://www.wpath.org/media/cms/Documents/Web%20Transfer/SOC/Standards%20of%20Care%20V7%20-%202011%20WPATH.pdf . Accessed September 10, 2017
• 6 Wylie K, Knudson G, Khan SI, Bonierbale M, Watanyusakul S, Baral S. Serving transgender people: clinical care considerations and service delivery models in transgender health. Lancet 2016; 388 (10042): 401-411 . Doi: 10.1016/S0140-6736(16)00682-6
• 7 Costa EMF, Mendonça BB. Clinical management of transsexual subjects. Arq Bras Endocrinol Metabol 2014; 58 (02) 188-196 . Doi: 10.1590/0004-2730000003091
• 8 Hembree WC, Cohen-Kettenis PT, Gooren L. , et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2017; 102 (11) 3869-3903 . Doi: 10.1210/jc.2017-01658
• 9 Irwig MS. Testosterone therapy for transgender men. Lancet Diabetes Endocrinol 2017; 5 (04) 301-311 . Doi: 10.1016/S2213-8587(16)00036-X
• 10 Gardner IH, Safer JD. Progress on the road to better medical care for transgender patients. Curr Opin Endocrinol Diabetes Obes 2013; 20 (06) 553-558 . Doi: 10.1097/01.med.0000436188.95351.4d
• 11 Bishop BM. Pharmacotherapy considerations in the management of transgender patients: a brief review. Pharmacotherapy 2015; 35 (12) 1130-1139 . Doi: 10.1002/phar.1668
• 12 Costantino A, Cerpolini S, Alvisi S, Morselli PG, Venturoli S, Meriggiola MC. A prospective study on sexual function and mood in female-to-male transsexuals during testosterone administration and after sex reassignment surgery. J Sex Marital Ther 2013; 39 (04) 321-335 . Doi: 10.1080/0092623X.2012.736920
• 13 Van Caenegem E, Wierckx K, Taes Y. , et al. Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI). Eur J Endocrinol 2015; 172 (02) 163-171 . Doi: 10.1530/EJE-14-0586
• 14 Caanen MR, Schouten NE, Kuijper EAM. , et al. Effects of long-term exogenous testosterone administration on ovarian morphology, determined by transvaginal (3D) ultrasound in female-to-male transsexuals. Hum Reprod 2017; 32 (07) 1457-1464 . Doi: 10.1093/humrep/dex098
• 15 Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med 2013; 10 (12) 3129-3134 . Doi: 10.1111/jsm.12319
• 16 Bourgeois AL, Auriche P, Palmaro A, Montastruc JL, Bagheri H. Risk of hormonotherapy in transgender people: Literature review and data from the French Database of Pharmacovigilance. Ann Endocrinol (Paris) 2016; 77 (01) 14-21 . Doi: 10.1016/j.ando.2015.12.001
• 17 Elamin MB, Garcia MZ, Murad MH, Erwin PJ, Montori VM. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol (Oxf) 2010; 72 (01) 1-10 . Doi: 10.1111/j.1365-2265.2009.03632.x